Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New licensing in nucleic acid technologies
March 2020
SHARING OPTIONS:

MADISON, Wis.—Dianomi Therapeutics Inc. shared news last month that it had licensed a second suite of IP from the Wisconsin Alumni Research Foundation (WARF) to expand the use of its Mineral Coated Microparticle technology into nucleic acid therapy. The new IP is related to compositions and methods for delivering nucleic acid-based therapies, and includes issued U.S. patents and pending U.S and international patent applications. Dianomi retains exclusive, global rights to pursue nucleic acid therapeutics independently and build out its commercialization and development programs with other entities.
 
"This new suite of intellectual property expands the capability of Dianomi's core technology into new indications and markets having significant commercial and clinical interest," said Martin Ostrowski, chief operations officer and general counsel of Dianomi. "We're thrilled to strengthen our relationship with WARF and continue developing the platform applicability of our technological and clinical programs to improve patient care."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.